Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657438 | 0.92 | HRH3 (0.56) | HRH3KDM4ESMN1; SMN2HTR1AHTR2A | |
| SCHEMBL5657710 | 0.90 | HTR1A (0.59) | HRH3KDM4ESMN1; SMN2HTR1AHTR2A | |
| SCHEMBL5657920 | 0.87 | HTR1A (0.47) | HRH3KMT2ASMN1; SMN2HTR1AHTR2A | |
| SCHEMBL5654888 | 0.86 | ALDH1A1 (0.57) | HRH3KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5655946 | 0.86 | HRH3 (0.53) | HRH3KMT2A | |
| SCHEMBL5657183 | 0.85 | DRD2 (0.55) | HRH3HTR1AHTR2A | |
| SCHEMBL5656315 | 0.85 | HTR1A (0.47) | HRH3SMN1; SMN2HTR1AHTR2A | |
| SCHEMBL5658252 | 0.84 | ALDH1A1 (0.59) | HRH3KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5657866 | 0.83 | MAPT (0.47) | KDM4EKMT2ATP53HTR1ATHRB | |
| SCHEMBL5656937 | 0.83 | MAPT (0.47) | KMT2ATP53HTR1ATHRBHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | CEREP (FR) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | HTR4, HTR5A, HTR3C | HRH3 129/4885KDM4E 512/4885MEN1 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.